Tylenol Autism Mass Tort Case Leads
Connect with families whose children were diagnosed with autism or ADHD following prenatal acetaminophen exposure — a docket revived by the Second Circuit in July 2026.
Tylenol & Acetaminophen Autism Litigation
MDL 3043, consolidated in the Southern District of New York, alleges that prenatal exposure to acetaminophen — the active ingredient in Tylenol and hundreds of store-brand analgesics — is associated with autism spectrum disorder and ADHD, and that manufacturers and retailers failed to warn. The district court excluded plaintiffs' general causation experts in December 2023 and entered judgment for the defense. On July 13, 2026 the Second Circuit reversed in a unanimous panel decision, restoring more than 500 claims. Our campaigns identify mothers who used acetaminophen during pregnancy and whose children carry a qualifying neurodevelopmental diagnosis.
Associated Conditions
- Autism spectrum disorder (ASD)
- Attention deficit hyperactivity disorder (ADHD)
- Developmental delay with a formal diagnosis
- Speech and language delay diagnosed alongside ASD
Claimant Eligibility
- Biological mother used acetaminophen during pregnancy
- Documented use beyond isolated, single-dose exposure
- Child diagnosed with autism spectrum disorder or ADHD by a qualified provider
- Diagnosis records or provider identification available
- Claim not previously filed or dismissed with prejudice
Why Law Firms Choose Us
Exclusive Leads
Every lead is yours alone. We never resell or share claimant information with competing firms, guaranteeing you first-mover advantage on every case.
Pre-Qualified Claimants
Our intake specialists screen every potential claimant against your specific case criteria before delivery, so your team only speaks with viable cases.
Live Transfer
Qualified claimants are transferred directly to your intake team in real time, maximizing conversion rates and reducing time-to-retainer.
Tylenol legal marketing campaigns: how we acquire cases
Tylenol case acquisition runs as a multi-channel program, not a single ad buy. Product liability and class action claimants research their condition long before they contact a lawyer, so we meet potential clients at each stage — paid demand capture for people already searching, paid social and traditional media for people who have not yet connected their injury to the litigation, and organic search for the long research tail.
Digital marketing channels
- Google Ads and paid search demand capture
- Meta and paid social prospecting by exposure profile
- Mass tort search engine optimization for the research tail
- OTT and connected TV retargeting
Traditional media channels
- Broadcast and cable TV in qualifying DMAs
- Radio and streaming audio
- Direct response print in occupational verticals
- Earned media and litigation PR support
How the channel mix is built, budgeted, and measured is covered in our mass tort marketing guide. For intake handling once the lead lands, see mass tort intake.
Tylenol Autism Lawsuit Updates (July 2026)
Current status of the Tylenol Autism litigation, tracked monthly so your intake team and marketing spend stay aligned with where the docket actually is.
- MDL
- MDL 3043
- Court
- S.D.N.Y.
- Pending cases
- 500+ revived
- Reported
- July 2026
Current posture: Revived on appeal after two years of dormancy; remanded for further proceedings.
On July 13 the U.S. Court of Appeals for the Second Circuit reversed the district court in a unanimous 3-0 decision, reviving more than 500 lawsuits against Kenvue and retailer defendants over claims linking prenatal acetaminophen use to autism.
Judge Denise Cote of the Southern District of New York excluded the plaintiffs' general causation experts and subsequently entered judgment for the defense, effectively halting the litigation for the following two years.
Case counts and procedural posture are compiled from JPML MDL statistics reporting and public court dockets, and are provided for law firm campaign planning. This is not legal advice and is not a prediction of any case outcome.
Running a Tylenol mass tort marketing campaign
Common questions from law firms about Tylenol lawsuit lead generation and campaign management.
- What does a Tylenol mass tort marketing campaign include?
- A Tylenol mass tort marketing campaign from Mass Tort Marketing Agency covers multi-channel strategy across Meta, Google PPC, OTT and connected TV, traditional media, and mass tort search engine optimization; compliant ad creative; TCPA-verified intake; claimant qualification against your Tylenol case criteria; and signed-retainer reporting. Performance is measured on cost per signed retainer, not raw lead volume.
- How do you generate Tylenol mass tort case leads?
- Tylenol mass tort case leads are generated through paid social and search campaigns aimed at the specific exposure and injury profile of the litigation, supported by organic content that captures claimants already researching their condition. Every lead is a real, consented claimant — we do not buy aggregated lists or resell shared data.
- What do Tylenol legal marketing campaigns cost?
- Tylenol legal marketing campaigns are quoted and reported on cost per signed retainer (CPSR), so spend ties directly to signed cases rather than lead count. Cost per retainer varies by tort based on claimant prevalence, media competition, and how tight your case criteria are. We scope a per-tort figure before any spend commitment.
- Are Tylenol leads exclusive to my firm?
- Yes. Every Tylenol lead is delivered to one firm only — never resold, syndicated, or shared with competing firms. Your firm owns the contact data, consent records, and call recordings.
- How are Tylenol claimants qualified before delivery?
- Each Tylenol claimant is screened against tort-specific facts (exposure windows, injury markers, and state eligibility) and carries a certified TrustedForm or Jornaya consent record — preserving the exact disclosure language shown at submission — before the lead reaches your intake team.
- How fast can a Tylenol case acquisition program scale?
- A Tylenol mass tort case acquisition program typically moves from scoping to live media inside two weeks, with volume ramped against your docket capacity rather than pushed to a fixed budget. Volume can be scaled up or down by tort month to month as the litigation posture changes.
- Is the Tylenol autism litigation still active in 2026?
- Yes. On July 13, 2026 the U.S. Court of Appeals for the Second Circuit reversed the district court in a 3-0 decision and revived more than 500 lawsuits against Kenvue and retailer defendants, overturning the December 2023 expert-exclusion ruling by Judge Denise Cote. The litigation is live again and firms are rebuilding inventory.
- Who qualifies for a Tylenol acetaminophen claim?
- Claims generally involve a biological mother who used acetaminophen during pregnancy and a child later diagnosed with autism spectrum disorder or ADHD. Screening captures the trimester and frequency of use, product and retailer identification where available, the diagnosis date, and the diagnosing provider.
- Why is timing important on Tylenol case acquisition right now?
- The Second Circuit revival reopened a docket that most firms had written off, and media costs on this tort fell sharply during the two years it was dormant. Firms building inventory in the window before competition returns to pre-2023 levels are acquiring at materially lower cost per signed retainer.
Get Tylenol campaign pricing on a 30-minute call
We will walk your Tylenol case criteria, current cost per signed retainer, and the volume your docket can absorb — and tell you plainly if this tort is not a fit right now.
See how every lead is qualified on our mass tort leads page, read the full mass tort marketing guide, or compare providers in our top mass tort marketing firms guide.